Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia-CliniExpert
Magrolimab - Multiple Myeloma Clinical Trials
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma | Future Oncology
Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner (NASDAQ:FTSV) | Seeking Alpha
PhI/II AZA/VEN/MAG - Slideset Download - | CCO
FORTY SEVEN, INC.
New Research on Magrolimab Provides Key Insights as Gilead Rapidly Expands Research in AML | Leukemia and Lymphoma Society
Magrolimab + Aza for AML - Slideset Download - Clinical Oncology 2022 | CCO
Magrolimab for Solid Tumors Clinical Trial 2023 | Power
Forty Seven (FTSV) On A Roll, Up Over 300% In 2 Months
ASCO News - Magrolimab in Combination with Azacitidine Demonstrates Durable Activity in Untreated MDS & AML | Leukemia and Lymphoma Society
Magrolimab plus azacitidine results in promising activity in higher-risk MDS patients
Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI (NASDAQ:FTSV) | Seeking Alpha
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients | Leukemia and Lymphoma Society
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy | Signal Transduction and Targeted Therapy
CD47-SIRPα Drug Target Minireview - Drug Hunter
EHA Library - The official digital education library of European Hematology Association (EHA)
JCM | Free Full-Text | Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
Cells | Free Full-Text | Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma - ScienceDirect
Magrolimab + Azacitidine vs Venetoclax in AML
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody) - Tan - 2022 - Internal Medicine Journal - Wiley Online Library
Efficacy of magrolimab + azacitidine in untreated AML and MDS patients. | Download Scientific Diagram
